Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Interferon Beta Combined With Vitamin D on Relapsing Remitting Multiple Sclerosis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients with a diagnosis of RRMS according to the McDonald criteria (2005)~* At least 18 years of age~* Patients are treated with IFN-beta for RRMS. The decision to treat with IFN beta will be independent from this study protocol.~* Patients will be either newly diagnosed, who are going to start IFN beta therapy for the first time or RRMS patients who suffer from FLS while being treated with IFN beta.~* Insufficient blood levels of 25-hydroxy-vitamin D (below 75nmol/l according to current definitions.~* EDSS score up to 7~* Willing and able to give informed consent~Exclusion Criteria:~* Patients having abnormalities of vitamin D related hormonal system other than low dietary intake or decreased sun exposure will be excluded. Namely, malabsorption \[Celiac, Whipple, Inflammatory bowl disease, Intestinal bypass surgery, Short bowel syndrome, Cirrhosis, Nephrotic syndrome, Hyperthyroidism, Renal failure \[creatinine clearance of less than 40 ml/min\], Rickets, Hypoparathyroidism, Hypercalcemia at baseline, known malignancy, granulomatous disorders (Sarcoidosis, Tuberculosis, Silicosis) and Lymphomas.~* Patients who take medications that influence vitamin D metabolism, other than corticosteroids, will be also excluded. Namely, Orlistat, Anticonvulsants \[Phenobarbital, Primidone, Phenytoin\], Rifampin, Isoniazide, ketoconazole, 5FU and Leucovorin~* Patients with conditions with increased susceptibility to hypercalcemia will be excluded too: known arrhythmia or heart disease, treatment with Digitalis, or Hydrochlorothiazide.and those who suffer from nephrolithiasis.~* Other Central Nervous System disorders than RRMS~* Psychiatric disorders such as psychosis, bipolar disorder or substance abuse~* Pregnancy~* Contra-indication to treatment with IFN-beta

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- High dose vitamin D (Type: EXPERIMENTAL): 800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
- Low dose vitamin D (Type: ACTIVE_COMPARATOR): 800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution

Based on this trial design, predict the completion outcome and termination type (if applicable).